Product
nilotinib
Aliases
AMN107
1 clinical trial
1 indication
Indication
Chronic Myeloid LeukemiaClinical trial
A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on NilotinibStatus: Active (not recruiting), Estimated PCD: 2015-11-26